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Molecular assays can provide critical information for malaria diagnosis, speciation, and drug resistance, but
their cost and resource requirements limit their application to clinical malaria studies. This study describes
the application of a resource-conserving testing algorithm employing sample pooling for real-time PCR assays
for malaria in a cohort of 182 pregnant women in Kinshasa. A total of 1,268 peripheral blood samples were
collected during the study. Using a real-time PCR assay that detects all Plasmodium species, microscopy-
positive samples were amplified individually; the microscopy-negative samples were amplified after pooling the
genomic DNA (gDNA) of four samples prior to testing. Of 176 microscopy-positive samples, 74 were positive
by the real-time PCR assay; the 1,092 microscopy-negative samples were initially amplified in 293 pools, and
subsequently, 35 samples were real-time PCR positive (3%). With the real-time PCR result as the referent
standard, microscopy was 67.9% sensitive (95% confidence interval [CI], 58.3% to 76.5%) and 91.2% specific
(95% CI, 89.4% to 92.8%) for malaria. In total, we detected 109 parasitemias by real-time PCR and, by pooling
samples, obviated over 50% of reactions and halved the cost of testing. Our study highlights both substantial
discordance between malaria diagnostics and the utility and parsimony of employing a sample pooling strategy
for molecular diagnostics in clinical and epidemiologic malaria studies.
Malaria causes nearly 250 million clinical episodes every
year (49), but diagnosis remains challenging (23). Microscopic
examination of thin or thick smears of peripheral blood can,
under optimal conditions, provide information on infecting
species and infection severity, but in many areas of endemicity,
the operating characteristics of microscopy are poor (34). Mi-
croscopic examination requires highly trained personnel for
smear interpretation, and even well-trained microscopists fre-
quently miss mixed-species infections. Furthermore, low-level,
“submicroscopic” parasitemia which is below the detectable
limit of blood smears is common in settings of acquired host
immunity (2) or exposure to antimalarials (27). Though rapid
antigen tests detect parasites quickly and cheaply, they cannot
provide data relevant to clinical malaria studies of multispecies
infections, drug resistance genotypes, and parasite burden
(51).
PCR may represent a better alternative for surveillance in
some situations. Conventional and real-time PCRs can provide
information on parasite density (1), infecting species (41), and
drug resistance alleles (50), all with high degrees of sensitivity
(42). However, large-scale application of PCR to malaria trials
and surveillance has not been implemented, largely because of
the cost and human resource requirements of molecular diag-
nostics.
Pooling samples prior to diagnostic testing for low-preva-
lence gene targets in a population promises an opportunity to
conserve resources without sacrificing diagnostic certainty.
First proposed for syphilis screening (14), the technique has
been successfully employed to screen blood donors for anti-
bodies to HIV (15), hepatitis B virus (11), and hepatitis C virus
(18) and to diagnose acute HIV infections by using PCR (37).
In testing algorithms that employ this strategy, the number of
samples included in each pool depends on the expected prev-
alence of the disease under study and the characteristics of the
diagnostic test. If a pool tests positive, the individual samples
comprising the pool are evaluated in a second round of testing.
Depending on the expected prevalence of a target condition,
pooling can obviate 90% of individual tests (47), with signif-
icant resource savings. Additionally, pooling is usually done
robotically, limiting technician time.
Malaria control programs in areas of endemicity are produc-
ing significant decreases in clinical malaria episodes and par-
asite densities (5, 8, 22, 32, 45), and molecular diagnostics may
become more critical in detecting parasitemias. Additionally,
pooling samples for molecular diagnosis of malaria could make
real-time PCR assays more feasible for large, clinical, re-
source-limited malaria studies. A previous longitudinal cohort
of 182 pregnant women in Kinshasa documented high rates of
antenatal malaria by blood smear and an association between
repeated infection and intrauterine growth retardation (24).
We employed a sample pooling/real-time PCR testing strategy
for malaria for both quality control and investigation of the
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impact of submicroscopic parasitemia on birth outcomes.
Herein, we report the development and results of this novel
molecular testing strategy.
MATERIALS AND METHODS
Patient enrollment and sample collection. The study was conducted at a single
antenatal clinic in Kinshasa, Democratic Republic of the Congo (DRC), to
determine the effect of malaria on intrauterine growth retardation. Briefly, all
pregnant women 17 years of age with estimated gestational ages of 24 weeks
were screened for inclusion; after being screened by ultrasound, women with
confirmed gestational ages of 23 weeks were enrolled between May 2005 and
2006 and followed longitudinally until delivery. All women received both inter-
mittent preventive therapy with sulfadoxine-pyrimethamine and an insecticide-
treated bed net in accordance with DRC national guidelines. At each scheduled
visit, acute visit, and delivery, blood was collected and both prepared as a thick
smear and applied to filter paper (Schleicher & Schuell 903 specimen paper).
Blood smears were interpreted on-site by a trained microscopist. For quality
assurance, a random sample of 10% of the blood smears was reviewed by a
second trained microscopist, who was masked to the initial smear results. All
women provided written informed consent at enrollment, and the study was
approved by the Institutional Review Boards of the University of North Carolina
at Chapel Hill and the Kinshasa School of Public Health.
Filter papers with blood spots were placed in individual plastic bags with
desiccant and stored at 20°C. They were transported to the United States,
where three 0.6-cm-diameter punches were punched from each card and depos-
ited into a single well of a 96-well deep-well plate. Genomic DNA (gDNA) from
plates of punches was extracted using a QIAamp 96 DNA blood kit (Qiagen,
Germantown, MD) with a vacuum manifold in accordance with the manufacturer’s
protocol. Genomic DNA was eluted into 150 l of eluate and stored at 4°C.
Design and validation of the pan-species real-time PCR assay with pooling.
Primer and probe sequences for the block 9 region of the gene encoding the
small subunit (18S) of plasmodium rRNA (ribosomal DNA [rDNA]) were mod-
ified from a published protocol which detected between 1 and 10 copies of the
target DNA and was specific to plasmodium 18S DNA (Table 1 gives all oligo-
nucleotide sequences) (38). The ability of the assay to detect different malaria
species and strains was evaluated by testing the assay with gDNA from Plasmo-
dium falciparum strain 3d7 (MR4 no. MRA-102G; ATCC, Manassas, VA);
gDNA from Plasmodium vivax strain Nicaragua (MR4 no. MRA-340G); and
plasmids containing the 18S rDNA genes from P. falciparum, P. vivax, Plasmo-
dium ovale, and Plasmodium malariae (MR4 no. MRA-177, MRA-178, MRA-
179, and MRA-180, respectively). The sensitivity of the assay was determined by
evaluating dilutions of P. falciparum gDNA. Real-time PCR was carried out with
25-l reaction mixtures consisting of 2 l of DNA, 12.5 l of 2 TaqMan
Universal PCR MasterMix (Applied Biosystems, Foster City, CA), forward and
reverse primers at 1,000 nM, and VIC-labeled minor-groove binding (MGB)
probe at 200 nM. The cycling conditions for the Applied Biosystems 7300 system
were 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for
1 min.
In order to evaluate the ability of the pan-species assay to diagnose malaria
from pooled samples, P. falciparum gDNA was used to create 10 artificial test
pools. Each pool was composed of 2 l from each of 10 components; the
components were either water or specified concentrations of parasite gDNA
(0.001 ng/l to 1 ng/l). Two pools contained only water, and eight pools had a
range of gDNA depending on the initial amount of gDNA in each component.
The personnel testing the pools were masked to the contents of the components.
All real-time PCRs were run with the Applied Biosystems 7300 system, and all
amplification curves were evaluated with ABI 7300 system sequence detection
software, version 1.3.
Sample pooling and pan-species detection. Figure 1 illustrates the sample
testing algorithm. Microscopy-positive samples were individually tested in dupli-
cate using 4 l of extracted DNA. For microscopy-negative samples, the optimal
pool size for testing was determined using an online calculator (http://www.bios
.unc.edu/mhudgens/optimal.pooling.b.htm [last accessed 3 July 2009]), and 10
l quantities of these samples were combined in pools of 4 original samples.
Pools were then amplified in 25-l reaction mixtures consisting of 8 l of pooled
genomic DNA and reagent concentrations identical to those described above for
the pan-species assay. For pools demonstrating amplification, the four individual
constituent samples were amplified as described above for the microscopy-pos-
itive samples. All reactions were run in duplicate on reaction plates that included
positive controls of P. falciparum 3D7 gDNA and negative controls. Pooling and
subsequent distribution of samples to reaction plates were facilitated by the use
of an epMotion 5070 robot (Eppendorf, Hamburg, Germany).
For quality assurance of the DNA extraction, microscopy-positive samples
without amplification in the pan-species assay were subsequently amplified in
assays targeting the human RNase P gene and the P. falciparum lactate dehy-
drogenase gene (Pfldh). The human RNase P assay consisted of 25-l reaction
mixtures with 1 l genomic DNA, 1.25 l RNase P reaction mixture (Applied
Biosystems), and 12.5 l TaqMan Universal PCR MasterMix (Applied Biosys-
tems). The Pfldh assay consisted of 25-l reaction mixtures with 2 l of genomic
DNA, 12.5 l of TaqMan Universal PCR MasterMix, forward and reverse
TABLE 1. Primer and probe sequences
Reagent Sequencec Reference or source
Primersa
Pan-species forward GTT AAG GGA GTG AAG ACG ATC AGA TA 38
Pan-species reverse AAC CCA AAG ACT TTG ATT TCT CAT AAG 38
P. falciparum 18S rDNA forward ATT GCT TTT GAG AGG TTT TGT TAC TTT 46
P. falciparum 18S rDNA reverse GCT GTA GTA TTC AAA CAC AAT GAA CTC AA 46
P. ovale 18S rDNA forward CCG ACT AGG TTT TGG ATG AAA GAT TTT T 39
P. ovale 18S rDNA reverse CAA CCC AAA GAC TTT GAT TTC TCA TAA 46
P. malariae 18S rDNA forward AGT TAA GGG AGT GAA GAC GAT CAG A 46
P. malariae 18S rDNA reverse CAA CCC AAA GAC TTT GAT TTC TCA TAA 46
Human GAPDH forward CCT CCC GCT TCG CTC TCT This study
Human GAPDH reverse GCT GGC GAC GCA AAA GA This study
P. falciparum LDH forward ACG ATT TGG CTG GAG CAG AT 36
P. falciparum LDH reverse TCT CTA TTC CAT TCT TTG TCA CTC TTT C 36
MGB probesb
Pan-species VIC-TCG TAA TCT TAA CCA TAA AC 38
P. falciparum FAM-CAT AAC AGA CGG GTA GTC AT 46
P. ovale VIC-CGA AAG GAA TTT TCT TAT T 38
P. malariae FAM-ATG AGT GTT TCT TTT AGA TAG C 46
Human GAPDH VIC-CCT CCT GTT CGA CAG TCA GCC GC This study
TaqMan probeb (P. falciparum LDH) FAM-GTA ATA GTA ACA GCT GGA TTT ACC AAG GCC CCA-TAMRA 36
a Synthesized by MWG/Operon Biotech (High Point, NC) and resuspended in molecular-grade water. LDH, lactate dehydrogenase.
b Synthesized by Applied Biosystems (Foster City, CA) and diluted in Tris-EDTA Buffer (FisherBioTech, Fair Lawn, NJ).
c “FAM” and “VIC” denote fluorescent dyes.
VOL. 48, 2010 SAMPLE POOLING FOR MALARIA PCR 513
primers at 300 nM, and 6-carboxyfluorescein (FAM)–6-carboxytetramethylrho-
damine (TAMRA) probe at 200 nM (36).
Design and validation of the real-time PCR speciation assay. PCR primers
and probes were adapted from previously published real-time PCR assays for
speciation of malaria (39, 46); P. vivax is exceptionally rare in Central Africa (10)
and was excluded. The assay was designed to amplify each sample in parallel in
two duplex reactions. One reaction mixture consisted of 2 l of DNA, 12.5 l of
the FastStart high-fidelity PCR system (Roche, Indianapolis, IN), P. falciparum
18S rDNA forward and reverse primers at 300 nM, P. falciparum rDNA FAM-
labeled MGB probe at 200 nM, P. ovale 18S rDNA forward and reverse primers
at 300 nM, P. ovale rDNA VIC-labeled MGB probe at 200 nM, and molecular-
grade water added to give a total reaction volume of 25 l. The parallel reaction
mixture consisted of 2 l of genomic DNA, 12.5 l of the FastStart high-fidelity
PCR system (Roche), P. malariae 18S rDNA forward and reverse primers at 300
nM, P. malariae rDNA FAM-labeled MGB probe at 200 nM, human glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) forward and reverse primers at
300 nM, GAPDH VIC-labeled MGB probe at 200 nM, and molecular-grade
water added to give a total reaction volume of 25 l. Human GAPDH primers
and probes were designed with Primer Express version 3.0 (Applied Biosystems).
The cycling conditions for the Applied Biosystems 7300 system were 50°C for 2
min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min.
To evaluate the specificity of the speciation assay, this assay was tested with the
same gDNA and plasmid DNA used to evaluate the pan-malaria species assay.
Because P. falciparum is the most common species causing malaria in the study
region and would be dominant in mixed infections, the assay was tested to
determine its ability to diagnose mixed infections with low abundances of P. ovale
and P. malariae. Samples that contained 0.01 ng/l of P. falciparum plasmid and
2.5 ng/l of human DNA were prepared, in addition to P. ovale or P. malariae
DNA ranging from 0.01 ng to 0.000001 ng/l of plasmid.
Speciation of positive samples. Samples demonstrating amplification in the
pan-species assay were amplified with the speciation real-time PCR assay. All
reactions were amplified in duplicate, and all reaction plates included three
standards: a positive control consisting of mixed P. falciparum, P. malariae, and
human genomic DNA; a positive control consisting of mixed P. falciparum, P.
ovale, and human genomic DNA; and a negative control.
Statistical analysis. Data were entered into Microsoft Excel 2003 (Microsoft,
Redmond, WA) and were imported into SAS, version 9.1.3 (SAS, Cary, NC) for
analysis. The sensitivity and specificity of peripheral blood microscopy diagnosis
were calculated using real-time PCR as the referent standard. Kappa coefficients
were used to quantify agreement between diagnostic outcomes. Pearson’s cor-
relation coefficient was used to examine the relationship between real-time PCR
cycle threshold (CT) values and microscopy-based parasite densities.
RESULTS
Study sample. A total of 1,111 antenatal clinic attendees
were screened for inclusion in the study; 370 women met the
screening criteria and, after gestational age was determined by
ultrasound, 182 gave consent and were enrolled. Table 2 de-
scribes the study cohort. The mean age of the cohort was 27.5
years (standard deviation [SD], 5.3 years), and there were 47
(25.8%) primigravidae and 26 (14.3%) secundigravidae. Five
participants were infected with HIV. From the 182 women,
1,268 blood samples were available for both microscopy and
molecular analysis. Full details of the study have been pub-
lished elsewhere (24).
FIG. 1. Sample processing and assay work flow schematic. Microscopy-positive samples were amplified directly in the pan-species assay, and
positive samples were subsequently tested in the speciation assay. Microscopy-negative samples were first grouped into pools of four and then
amplified in the pan-species assay; the individual constituents of positive pools were then retested in the pan-species assay, and positive samples
were subsequently tested in the speciation assay.
TABLE 2. Study subject demographics (n  182)
Characteristic Value
Mean (SD) age (yr) .................................................................. 27.5 (5.3)
Mean (SD) gestational age (wk) at enrollment .................... 18.9 (2.8)
No. (%) of subjects with gravidity
Primigravid ............................................................................. 47 (25.8)
Secundigravid......................................................................... 26 (14.3)
Multigravid.............................................................................109 (59.8)
No. (%) of subjects HIV infected........................................... 5 (2.7)
Mean (SD) total no. of study visits ........................................ 6.3 (1.4)
Mean (SD) no. of malaria treatments received .................... 2.5 (0.8)
No. (%) of visits to subjects who always slept
under an insecticide-treated bed net during the
previous 2 wka ...................................................................531 (66.6)
a Bed net use was assessed for 797 regular study visits.
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Performance of real-time PCR assays. The pan-species assay
reproducibly detected gDNA from stock strains of P. falcipa-
rum and P. vivax at a concentration of 0.001 ng/l (39 parasites
per microliter, based on an estimated genome size of 23 Mb),
with an average CT value of 32.63 (SD, 0.008).
The pooling assay was tested in masked fashion with artifi-
cial test pools. The two pools without gDNA failed to amplify,
and the eight pools with gDNA successfully amplified with
various CT values. The assay successfully detected the pool
with the lowest DNA concentration (0.001 ng/l) (Fig. 2A),
which was a single low-concentration sample pooled with nine
negative samples; this indicated that the assay was sensitive
enough to diagnose a low-level infection, even when tested
with a pool of 10 samples. The individual samples from each
pool were then tested, and the assay correctly identified all
samples with malaria DNA without false-positive results.
For the speciation assay, the assay correctly identified sam-
ples containing stock and 18S plasmid DNA from each malaria
species. The multiplex assay was also compared to each species
assay run as a monoplex assay: for each sample, no differences
in CT values were observed between the monoplex and multi-
plex formats, indicating an absence of significant competition
in the multiplex format. Additionally, the assay was able to
detect the lowest concentration of plasmid accurately for both
species (approximately 4 parasites per reaction, based on 6
copies of the gene and a 23-Mb genome) (Fig. 2B).
Comparison of microscopy and real-time PCR. Overall, 176
of 1,268 blood smears were interpreted as positive (14%) by
microscopy. A second microscopist reviewed 140 randomly
selected smears and concurred on 11 of the 12 smears initially
interpreted as positive and 127 of the 128 smears initially
interpreted as negative (  0.91; 95% confidence interval
[CI], 0.78 to 1.0). During real-time PCR analysis, 109 DNA
samples demonstrated amplification at the plasmodium 18S
rDNA locus (9%). Of the 176 microscopy-positive samples, 74
(42%) were positive by direct amplification in the pan-species
assay. After pooling and amplification of the 1,092 microscopy-
negative samples, 35 additional individual samples were posi-
tive in the pan-species assay. All positive controls amplified
appropriately; all negative controls failed to amplify. All mi-
croscopy-positive/pan-species PCR-negative samples demon-
strated amplification in assays targeting the human RNase P
gene, confirming successful extraction of DNA from the filter
paper. In addition, 2 of the 102 microscopy-positive/pan-spe-
cies PCR-negative samples amplified at the Pfldh gene, dem-
onstrating that the sensitivity of the assay is not 100%.
With real-time PCR as the referent for malaria diagnosis,
the sensitivity of microscopy was low at 67.9% (95% CI, 58.3%
to 76.5%) and the specificity was higher at 91.2% (95% CI,
89.4% to 92.8%) (Table 3). Overall, the agreement between
the results for microscopy and the real-time PCR assay was
moderate (  0.46; 95% CI, 0.39 to 0.54). For the 65 samples
that were positive by both microscopy and real-time PCR and
for which quantitative microscopy data were available, there
was a modest correlation between smear parasite density and
the CT value in the pan-species real-time PCR assay (Pearson
correlation coefficient, 0.39; P  0.01).
Speciation by real-time PCR. All 109 samples demonstrating
amplification in the pan-species assay also amplified in the
speciation assay. Pure P. falciparum parasitemias accounted for
104 infections, with P. falciparum mixed with P. malariae in 3
additional infections. One infection was purely P. malariae and
one purely P. ovale. The human GAPDH gene amplified from
all samples, and all positive species controls amplified appro-
priately.
Efficiency of sample pooling. With the conservative predic-
tions of a sensitivity of 95%, a specificity of 99%, and a 10%
prevalence of parasitemia, a pool size of four samples was
determined to achieve the greatest efficiency without sacrific-
ing test sensitivity. Thus, the 1,092 microscopy-negative sam-
ples were amplified by the pan-species assay in duplicate in 293
pools of four samples each, resulting in 586 reactions. Because
38 of these pools demonstrated amplification, a further 152
amplifications in duplicate were necessary to identify the 35
positive individual samples (in retrospect, three microscopy-
positive samples were inadvertently included in the pooled
sample set). In total, 890 amplifications were needed to iden-
tify the 35 microscopy-negative/pan-species PCR-positive sam-
ples. Because direct amplification of all microscopy-negative
samples in duplicate without pooling would have necessitated
2,184 reactions, this represents a reduction of 1,294 total re-
actions. In total, screening our entire cohort of 1,268 samples
with partial pooling required 1,242 reactions, a reduction of
1,294 (51%) from the 2,536 reactions necessary to screen all
samples without pooling (excluding control reactions). On the
basis of a conservative cost per reaction of approximately $1.25
(including the probe, primers, polymerase, and consumables),
directly amplifying all samples would have cost $3,170; our
pooling strategy reduced this total to $1,553, for a cost reduc-
tion of 51%, or $1,617.
DISCUSSION
This longitudinal study of malaria infection during preg-
nancy in Kinshasa demonstrates the reliability and parsimony
of a sample pooling strategy for detecting parasitemia by real-
time PCR. Additionally, this study documents substantial dis-
cordance between microscopic and molecular diagnoses of ma-
laria. We believe that these twin findings reinforce both the
feasibility and the necessity of incorporating molecular diag-
nostics for malaria into clinical studies.
Due to the effects of malaria on birth outcomes, prevention
of malaria during pregnancy is critical (13). Of the 182 women
in our trial, 57 (31%) were parasitemic by PCR either during
pregnancy or at delivery, similar to the rates reported in other
studies (43), including those involving subjects from Kinshasa
(25). Though it can be decreased substantially by intermittent
preventive therapy with antimalarials (19), parasitemia is more
prevalent during pregnancy (7) and is often asymptomatic (29).
Among nonpregnant adults in regions where malaria is en-
demic, the prevalence of asymptomatic parasitemia is high (3,
17), and the application of PCR diagnoses more cases than
standard blood smears (2, 12). Similarly, PCR may provide a
more reliable method of screening for parasites in pregnant,
semi-immune asymptomatic individuals.
Because asymptomatic populations typically have low para-
site burdens (12), a sensitive screening test is essential, and
pooling samples can potentially diminish sensitivity of detec-
tion of the test target in a pool of samples (47). Prior to
application, the described assay was validated for detection of
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the equivalent of 39 parasites/l in a single sample pooled with
nine parasite-free samples (i.e., 4 parasites/l ultimately);
the assay was less intensive in application, with fewer samples
pooled and a larger amount of genomic DNA included in each
reaction. Current real-time PCR assays can detect 40 para-
sites/l (35, 38, 46), a standard with which our pooled assay
compares favorably.
Our study demonstrates significant resource savings with
pooling samples in comparison with direct testing of individual
samples in real-time PCR assays: in the subset of microscopy-
negative samples with a predicted low prevalence of para-
sitemia, the estimated cost saving of pooling, compared with
the cost of traditional testing, was over 50%. The efficiency,
and therefore the cost saving, associated with sample pooling is
primarily dependent on an accurate estimate of the prevalence
of the target condition (47). In our study, this saving could have
been improved by pooling in greater numbers with more-pre-
cise foreknowledge of the low prevalence of parasitemia in the
microscopy-negative samples. Pooling-related savings are in-
versely related to parasite prevalence; given the post-hoc prev-
alence of PCR positivity of 3% among the microscopy-negative
samples, pools of seven would have allowed for an obviation of
two-thirds of the reactions without sacrificing test sensitivity.
Adaptation of this pooling strategy should take into account
the predicted epidemiology of malaria in the study population.
In this study, only 68% of real-time PCR-positive samples
were detected by microscopy, despite both the use of a trained
and experienced primary microscopist and high levels of inter-
rater agreement with a second interpretation of a random
sample of positive and negative smears. This substantial dis-
cordance highlights the unreliability of the blood smear for
malaria diagnosis in some settings (34). The poor sensitivity of
blood smears may be exacerbated by the declines in incident
infections and parasite densities in many areas of endemicity
(8), and thus, clinical trials of vaccine efficacy, chemoprophy-
laxis, and antimalarial treatment may require detection meth-
ods of greater sensitivity to accurately determine exposures
and outcomes (16, 20, 30, 31).
Additionally, the low positive predictive value in our study,
in which only 42% of blood smear-positive samples demon-
strated amplification in real-time PCR assays, suggests that
blood smear use in clinical studies may also be compromised by
overdiagnosis and poor specificity. Though the specificity of
microscopy in our study was 91% (with real-time PCR as the
referent), the application of microscopy in a setting with a low
prevalence significantly compromised its positive predictive
value. This phenomenon has been observed in other studies
(26, 28, 44) and may have several causes: systematic errors in
thick smear preparation can produce false-positive interpreta-
tions because of red cell fragments, platelets, other blood el-
ements, or environmental particulate contamination (51), and
clinical approaches that bias toward overtreatment for malaria
may also bias laboratory personnel toward overdiagnosis (9).
Declines in parasite prevalence in areas where malaria is en-
demic (5, 8, 45) may further compromise the positive predic-
tive value of microscopy and limit the utility of microscopy for
case detection in clinical studies.
Conversely, this apparently poor specificity of blood smears
may actually reflect poor sensitivity on the part of the real-time
PCR assay. The sensitivities of PCR-based assays typically dif-
fer on the basis of common factors, such as sample quality,
real-time system, and cycling conditions, and can be compro-
mised by factors such as low target gene copy number (33),
competitive inhibition of amplification by related sequences
(6), and target sequence variation (48). Our pan-species
screening assay targeted a multicopy gene encoding the small
subunit of plasmodium ribosomal DNA, and the primers were
adopted from an assay which achieved a lower detection limit of
1 copy per 25-l reaction mixture (38). Most of the microscopy-
positive samples that failed to amplify in the pan-species assay
also failed to amplify in a second assay targeting a conserved
gene unique to P. falciparum (Pfldh), which is the preponder-
ant species in Kinshasa (21) and the predominant species in
pregnancy-associated malaria in Africa (7). Additionally, al-
though blood spot preservation and DNA extraction methods
can affect the yield of molecular diagnostics (4), successful
real-time amplification of a human gene indicates sufficient
DNA preservation and extraction as well as the absence of
significant PCR inhibitors. We believe that these represent
true false-positive blood smears.
For parasite detection, most clinical malaria studies rely
primarily on blood smears, and PCR-based diagnostics have
not been widely employed, due to a lack of resources in areas
where malaria is endemic. Given the ease and reliability of
storing blood on filter paper for downstream molecular anal-
ysis (40); the ability to detect parasite species (41), burden (1),
and antimalarial susceptibility (50); and the declines in parasite
rates observed in areas of endemicity after the implementation
of malaria control programs (5, 8, 45), molecular diagnostics
may become a more critical case detection method. In this
study, we demonstrate both the value-added diagnostic infor-
FIG. 2. Real-time PCR output from masked validation of pan-species and speciation assays using artificial test samples. Panel A shows the
output of real-time PCR testing with 5 artificial test pools (pools A to E) in the pan-species assay. Each pool contained 2 l of DNA from 10
samples. Pool A contained a total of 1.111 ng/l, divided among 4 samples, and pool B contained 1 ng/l of DNA in a single sample. Pools C, D,
and E contained DNA at total concentrations of 0.1, 0.01, and 0.001 ng/l, respectively. Panel B shows the output observed for the speciation
real-time PCR assay when tested on a sample with 0.01 ng/l of P. falciparum plasmid (Pf), 0.000001 ng/l of P. ovale plasmid (Po), and 2.5 ng/l
of human DNA (Hu). Delta Rn, fluorescent signal generated relative to background fluorescence.
TABLE 3. Comparison of results of microscopy and real-time PCR
for malaria detection
Microscopy result
No. of subjects with real-
time PCR result Total no. of
subjects
Positive Negative
Positive 74 102 176
Negative 35 1,057 1,092
Total 109 1,159 1,268
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mation provided by real-time PCR applied to a clinical study
and a resource-saving strategy for its application. We believe
that, for clinical malaria studies of prophylaxis, vaccine efficacy,
and drug therapy, molecular diagnostics are valuable as both
critical and robust measures of exposure and outcome.
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